Prostate Specific Antigen News and Research

RSS

PSMA PET/MRI can successfully determine the risk of prostate cancer recurrence

In men recently diagnosed with intermediate or high-grade prostate cancer, prostate specific membrane antigen (PSMA) PET/MRI can successfully determine whether their cancer is likely to return within two years of a prostatectomy.

6 Jan 2023

Study shows the prevalence of low-value prostate cancer screening in primary care clinics

Prostate cancer is the second-leading cause of cancer death in men with more than 34,000 deaths in the U.S. each year, according to the American Cancer Society.

4 Jan 2023

Rising Medicare costs linked to increased use of new prostate cancer therapies

Medicare costs for treatment of metastatic prostate cancer have risen sharply within the last 15 years – reflecting increased use of new medications under Medicare Part D, reports a study in Urology Practice, an Official Journal of the American Urological Association.

20 Dec 2022

Cambridge scientists develop a comprehensive tool for predicting individual's risk of prostate cancer

Cambridge scientists have created a comprehensive tool for predicting an individual's risk of developing prostate cancer, which they say could help ensure that those men at greatest risk will receive the appropriate testing while reducing unnecessary – and potentially invasive – testing for those at very low risk.

12 Dec 2022

Study identifies risk factors that increase Black men's susceptibility to early-onset prostate cancer

A family history of cancer and genetic variants that might be inherited appear to be important risk factors for Black men diagnosed with early-onset prostate cancer, a study involving Duke Health researchers has found.

29 Nov 2022

Study shows benefits of metastasis-directed therapy without ADT for oligorecurrent prostate cancer

For patients with solitary metastases from prostate cancer, an approach called metastasis-directed therapy (MDT) – focused treatment using surgery or radiation therapy, without androgen deprivation therapy (ADT) – can slow the time to cancer progression, reports a study in The Journal of Urology, an Official Journal of the American Urological Association

10 Nov 2022

Polygenic hazard score could be effective for predicting genetic risk of lethal prostate cancer

Tapping into the Million Veteran Program, an ongoing national research effort to learn how genes, lifestyle and military exposures affect the health of participants, researchers at University of California San Diego School of Medicine and the VA San Diego Healthcare System, with colleagues elsewhere, report that a polygenic hazard score based on 290 genetic variants could be an effective tool for predicting genetic risk of lethal prostate cancer.

31 Oct 2022

$38,398 for a single shot of a very old cancer drug

Dr. Josie Tenore and Paul Hinds were introduced by a mutual friend in 2017 and hadn't been going out long when she laid down the law: He had to get a physical.

26 Oct 2022

More intensive prostate cancer screening may reduce the risk of metastatic cancer later

In the face of conflicting evidence over the risks and benefits of routine prostate cancer screenings, a large, longitudinal analysis found Veterans Health Administration medical centers with lower prostate screening rates had higher rates of metastatic prostate cancer cases in subsequent years than centers with higher screening rates.

24 Oct 2022

Final results of the PATHFINDER study by GRAIL on multi-cancer early detection tests announced

A new press release announced the results of their interventional PATHFINDER study on the early detection of cancer using multi-cancer early detection (MCED) blood tests.

13 Sep 2022

Neoadjuvant NHAs followed by surgery can improve key outcomes in high-risk prostate cancer patients

For high-risk patients with prostate cancer, treatment with novel hormonal agents (NHAs) followed by surgery can reduce the risk of recurrent and progressive cancer, compared to initial treatment with surgery, suggests a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA).

12 Sep 2022

New study supports targeted screening program for prostate cancer

Data from the world's largest prostate cancer screening study provides further evidence to support the introduction of a targeted screening program for the disease, say researchers.

1 Jul 2022

Combined treatment approach proves to be beneficial for prostate cancer patients

Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy-;a commonly used hormone injection-;plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients' prostate cancer at bay for five years.

26 May 2022

Henry Ford Health offers a non-surgical treatment option for localized prostate cancer

Henry Ford Health is the first in Michigan to offer Robotic High Intensity Focused Ultrasound (HIFU) for the treatment of localized prostate cancer. This non-surgical treatment option spares surrounding healthy tissue, while allowing for a quicker treatment time and recovery for the patient.

10 May 2022

Study uncovers new regulator of prostate cancer metastasis

A transcription factor normally associated with androgen receptor activity in prostate cancer has a newly discovered role in controlling lipid biosynthesis, according to a Northwestern Medicine study published in Nature Genetics.

10 May 2022

Less PSA testing minimizes overdiagnosis but may lead to increase in metastatic prostate cancer cases

Over the past 15 years, public health authorities have downgraded recommendations for the prostate-specific antigen (PSA) test as a screening tool to reduce the overdiagnosis and overtreatment of men with low-grade prostate cancer.

22 Apr 2022

New findings could change treatment practice and lengthen survival for men with pN1 prostate cancer

Men with microscopic evidence of prostate cancer spreading to their pelvic lymph nodes (LNs) following the surgical resection of the prostate and pelvic lymph nodes (LN) are at a very high risk of dying from prostate cancer. Pelvic LN radiation therapy (RT) is a potentially curative treatment.

15 Mar 2022